Table 2 Surgical and anaesthesia characteristics
Parameter | Group S | Group SL | Group P | Group PL |
|---|---|---|---|---|
Sevoflurane | Sevoflurane +lidocaine | Propofol-TIVA | Propofol-TIVA + lidocaine | |
(n = 29) | (n = 30) | (n = 30) | (n = 30) | |
Type of surgical intervention (n,%) | ||||
Wide local excision with node dissection | 8(28) | 6(20) | 6(20) | 7(23) |
Modified radical mastectomy | 12(41) | 19(63) | 20(67) | 12(40) |
Radical mastectomy | 9(31) | 4(13) | 4(13) | 10(33) |
Simple mastectomy | 0 | 1(3) | 0 | 1(3) |
Postoperative pathologic staging (n,%) | ||||
Invasive breast carcinoma NST | 27(93) | 28(93) | 25(83) | 25(83) |
Invasive lobular carcinoma | 1(3) | 0 | 1(3) | 1(3) |
Adenoid cystic carcinoma | 0 | 0 | 0 | 1(3) |
In situ ductal carcinoma | 1(3) | 1(3) | 3(10) | 3(10) |
Mucinous adenocarcinoma with invasive breast carcinoma NST | 0 | 0 | 1(3) | 0 |
Intraductal papillary carcinoma | 0 | 1(3) | 0 | 0 |
Postoperative molecular typing (n,%) | ||||
Luminal A | 4(14) | 2(7) | 10(33) | 5(17) |
Luminal B(HER2 negative) | 17(59) | 16(53) | 9(30) | 15(50) |
Luminal B(HER2 positive) | 0 | 3(10) | 2(7) | 3(10) |
Erb-B2 overexpression | 1(3) | 2(7) | 4(13) | 2(7) |
Basal-like | 6(21) | 5(17) | 4(13) | 5(17) |
No available data | 1(3) | 2(7) | 1(3) | 0 |
Duration of surgery (min) | 82.55(20.41) | 84.43(21.74) | 76.83(28.53) | 77.57(26.63) |
Duration of anaesthesia (min) | 104.86(24.78) | 105.07(24.05) | 96.10(30.57) | 97.67(30.50) |
Intraoperative Midazolam (mg) | 3.03(0.48) | 2.97(0.32) | 3.03(0.37) | 3.03(0.32) |
Intraoperative Sufentanil (ug) | 18.15(2.90) | 17.80(1.95) | 18.17(2.21) | 18.16(1.93) |
Intraoperative Remifentanil (mg) | 0.99 (0.28) | 0.96 (0.27) | 1.10(0.45) | 0.95 (0.35) |
Intraoperative Etomidate (mg) | 18.15(2.90) | 17.80(1.95) | 18.17(2.21) | 18.16(1.93) |
Intraoperative Rocuronium (mg) | 43.84(7.39) | 40.05(6.49) | 41.54(7.00) | 39.65(6.43) |
Intraoperative HR | 66.03(11.20) | 64.23(11.22) | 63.83(6.83) | 64.03(9.64) |
Intraoperative MAP (mmHg) | 70.17(10.48) | 71.83(11.47) | 76.53(13.87) | 73.37(10.63) |